Bristol Myers Squibb (BMS) has completed its $13.1 billion acquisition of MyoKardia.
“We are excited to welcome MyoKardia colleagues to Bristol Myers Squibb,” said BMS Board Chair and CEO, Giovanni Caforio.
“The MyoKardia team has revolutionized cardiovascular treatments to address significant unmet medical needs, and we look forward to helping more patients together.
“With MyoKardia, we are bolstering our leading cardiovascular franchise and adding exceptional scientific capabilities, a potentially transformative new medicine with significant commercial potential and a promising pipeline of candidates.
“Cardiovascular remains an important therapeutic area for Bristol Myers Squibb with a strong legacy and a promising future.”
The deal sees BMS gain mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy (HCM), a chronic heart disease with high morbidity and patient impact.
A New Drug Application for mavacamten for the treatment of symptomatic obstructive HCM – based on data from the EXPLORER-HCM study – is expected to be submitted to the US FDA in the first quarter of 2021.